Acelrx pharmaceuticals reports third quarter 2022 financial results and provides corporate update

Initial niyad development batch successfully produced; preparations on track for an emergency use authorization submission dsuvia sales of $0.5m in the third quarter, a 217% increase over prior year $20.9 million in cash and short-term investments as of september 30, 2022 webcast and conference call to be held today at 4:30 p.m. edt hayward, calif.
ACRX Ratings Summary
ACRX Quant Ranking